Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Avacta Group plc ( (GB:AVCT) ) just unveiled an announcement.
Avacta Group plc has announced its preliminary results for the year ending December 31, 2024, highlighting its transformation into a dedicated oncology biopharmaceutical company. The company has made significant progress with its pre|CISION® platform, including the completion of Phase 1a trials for its lead asset FAP-Dox (AVA6000) and plans for Phase 1b and Phase 2 trials in various cancers. Avacta has also entered a strategic collaboration with Tempus to leverage AI for smarter trials and extended its cash runway into Q1 2026 through strategic divestments. The company is focused on establishing partnerships and securing long-term financing to support its innovative pipeline and enhance shareholder value.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
More about Avacta Group plc
Avacta Group plc is a clinical-stage life sciences company specializing in oncology biopharmaceuticals. It focuses on developing next-generation peptide drug conjugates (PDC) through its proprietary pre|CISION® platform, which targets anti-tumor payloads directly to tumors. This platform aims to enhance the efficacy and safety of cancer treatments by concentrating potent drugs in the tumor microenvironment while minimizing systemic toxicity.
Average Trading Volume: 1,993,067
Technical Sentiment Signal: Sell
Current Market Cap: £135.2M
Learn more about AVCT stock on TipRanks’ Stock Analysis page.